BARCLAYS PLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 4 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$28
-22.2%
23,996
-7.4%
0.00%
Q2 2023$36
+71.4%
25,905
+87.3%
0.00%
Q1 2023$21
-36.4%
13,830
-50.8%
0.00%
Q4 2022$33
-99.6%
28,109
+268.1%
0.00%
Q3 2022$9,000
-71.0%
7,637
-62.5%
0.00%
Q1 2022$31,00020,3600.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders